{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:26:08Z","timestamp":1788305168974,"version":"build-2803163510"},"reference-count":18,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Twice-weekly carfilzomib (27\u00a0mg\/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed\/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56\u00a0mg\/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56\u00a0mg\/m2 (KRd56; n\u00a0=\u00a0228) or twice-weekly 10-minute infusions of 27\u00a0mg\/m2 (KRd27; n\u00a0=\u00a0226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95%\u00a0CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95%\u00a0CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P\u00a0=\u00a0.0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of\u00a0patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95%\u00a0CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95%\u00a0CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013101","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T20:26:53Z","timestamp":1721334413000},"page":"5012-5021","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-6079","authenticated-orcid":false,"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania"},{"name":"3Department of Haematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7523-7510","authenticated-orcid":false,"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5283","authenticated-orcid":false,"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[{"name":"5First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Upchurch","sequence":"additional","affiliation":[{"name":"6Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belle","family":"Fang","sequence":"additional","affiliation":[{"name":"6Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshandra","family":"Talpur","sequence":"additional","affiliation":[{"name":"6Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Faber","sequence":"additional","affiliation":[{"name":"7Oncology Hematology Care, Inc, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"8Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Cellular Therapy, CIC U1402 CHU de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"suppl 1","key":"2024100813002043700_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-142376","article-title":"Multiple myeloma mortality incidence prevalence of disease - Mmy Mind Study","volume":"136","author":"Mart\u00ednez Cordero","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024100813002043700_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2024100813002043700_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.02.007","article-title":"How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients?","volume":"112","author":"Sonneveld","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2024100813002043700_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"2024100813002043700_bib5","volume-title":"Kyprolis (carfilzomib). Package insert","year":"2022"},{"issue":"8","key":"2024100813002043700_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024100813002043700_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024100813002043700_bib8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1185\/030079907X210543","article-title":"An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting","volume":"23","author":"Barrett-Lee","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2024100813002043700_bib9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024100813002043700_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"issue":"10245","key":"2024100813002043700_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"2024100813002043700_bib12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ajh.25498","article-title":"Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study","volume":"94","author":"Biran","year":"2019","journal-title":"Am J Hematol"},{"key":"2024100813002043700_bib13","article-title":"Effect of prolonged treatment with carfilzomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma","author":"Gruchet","year":"11-14  2020","journal-title":"Poster presented at: EHA Annual Meeting (virtual)"},{"key":"2024100813002043700_bib14","unstructured":"US National Library of Medicine; ClinicalTrials.gov\n          . A study comparing once-weekly vs twice-weekly carfilzomib in combination with lenalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (ARROW2). ClinicalTrials.gov identifier: NCT03859427. Accessed 1 March 2024. https:\/\/clinicaltrials.gov\/study\/NCT03859427."},{"issue":"2","key":"2024100813002043700_bib15","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"2024100813002043700_bib16","unstructured":"FDA\n          . Non-inferiority clinical trials to establish effectiveness. Guidance for industry. 2016. Accessed 1 March 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/non-inferiority-clinical-trials."},{"key":"2024100813002043700_bib17","unstructured":"EMA\n          . Guideline on the choice of the non-inferiority margin. 2005. Accessed 13 May 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-choice-non-inferiority-margin_en.pdf."},{"issue":"26","key":"2024100813002043700_bib18","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5012\/2245533\/blooda_adv-2024-013101-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5012\/2245533\/blooda_adv-2024-013101-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:58:53Z","timestamp":1728403133000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5012\/517073\/A-R-R-O-W-2-once-vs-twice-weekly-carfilzomib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":18,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013101","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}